[NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and for up to ten years after you stop taking these drugs to treat the cancer
Participants must be at least 18 years old, have newly diagnosed, previously untreated Stage III or IV classical Hodgkin lymphoma.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive study drug for approximately 6 months. Follow up will last up to 10 years.
Knight Information Line - firstname.lastname@example.org or 503-494-1080